

Journal

**Journal of Drug Targeting** >

Volume 25, 2017 - Issue 6

141 | 2 | 0  
Views | CrossRef citations | Altmetric

Review Article

# Recent developments in *trans*-sialidase inhibitors of *Trypanosoma cruzi*

Muhammad Kashif, Antonio Moreno-Herrera, Edgar E. Lara-Ramirez, Esther Ramírez-Moreno, Virgilio Bocanegra-García, Muhammad Ashfaq &amp; ...show all

Pages 485-498 | Received 10 Oct 2016, Accepted 29 Jan 2017, Accepted author version posted online: 31 Jan 2017, Published online: 20 Feb 2017

 Download citation <https://doi.org/10.1080/1061186X.2017.1289539> Check for updates

Seleccionar idioma ▼

Translator disclaimer



## Abstract

Chagas is a lethal chronic disease that currently affects 8–10 million people worldwide, primarily in South and Central America. *Trypanosoma cruzi* trans-sialidase is an enzyme that is of vital importance for the survival of the parasite due to its key role in the transfer of sialic acid from the host to the parasite surface and it also helps the parasite combat the host's immune system. This enzyme has no equivalent human enzyme; thus, it has become an interesting target for the development of inhibitors that combat the parasite. In this review, we summarize three classes of inhibitors (acceptor, donor and unrelated) with their inhibition values and their mode of action against this enzyme. Based on molecular docking, molecular dynamics and structure-activity relationship studies, it has been discovered that the molecules with –NH<sub>2</sub>, –OH and –COOH groups on an aromatic ring could be used as a scaffold for the development of new and potent *trans*-sialidase inhibitors due to their key interaction with active enzyme sites. In particular, carboxylic acid derivatives have importance over the sugar moiety due to their ease of synthesis and unique structure-activity relationship.

Keywords: *Trypanosoma cruzi*, trans-sialidase, inhibitors, carboxylic acid, molecular docking

## Additional information

### Funding

This work was supported by Consejo Nacional de Ciencia y Tecnología [CB-2014-01, 241615].

Login options

- [> Log in](#)
- [> Shibboleth](#)
- [> OpenAthens](#)

## Restore content access

- [> Restore content access for purchases made as guest](#)

## Purchase \*

[Save for later](#)

### Online



Article Purchase **24 hours access for USD 54.00**

Issue Purchase **30 days access for USD 498.00**

\* Local tax will be added as applicable

## People also read

### Novel drug discovery for Chagas disease >

Carolina B. Moraes et al.

Expert Opinion on Drug Discovery  
Volume 11, 2016 - Issue 5

**Published online:** 1 Apr 2016

Review

### Novel nanoparticulate systems for lung cancer therapy: an updated review >

Asadullah Madni et al.

Journal of Drug Targeting  
Volume 25, 2017 - Issue 6

**Published online:** 20 Feb 2017

Article

### *PTEN* and *TRAIL* genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma >

Fathia Zaki El Sharkawi et al.

Journal of Drug Targeting  
Volume 25, 2017 - Issue 6

**Published online:** 16 Feb 2017

Review

### Recent progress in drug delivery of pluronic P123: pharmaceutical perspectives >

Li-Yan Zhao et al.

Journal of Drug Targeting  
Volume 25, 2017 - Issue 6

**Published online:** 20 Feb 2017

Review

### Detection and treatment of *Trypanosoma cruzi*: a patent review (2011-2015) >

Juan B. Rodriguez et al.

Expert Opinion on Therapeutic Patents  
Volume 26, 2016 - Issue 9

**Published online:** 19 Jul 2016



Article

### *Trypanosoma cruzi* targets for new chemotherapeutic approaches >

Maria Nazaré C Soeiro et al.

Expert Opinion on Therapeutic Targets  
Volume 13, 2009 - Issue 1

**Published online:** 8 Dec 2008



Information for

- [Authors](#)
- [Editors](#)
- [Librarians](#)
- [Societies](#)

Help and info

- [Help](#)
- [FAQs](#)
- [Newsroom](#)
- [Contact us](#)
- [Commercial services](#)

Open access

- [Overview](#)
- [Open journals](#)
- [Open Select](#)
- [Cogent OA](#)

Connect with Taylor & Francis



[Copyright © 2018 Informa UK Limited](#) [Privacy policy & cookies](#) [Terms & conditions](#) [Accessibility](#)

Registered in England & Wales No. 3099067  
5 Howick Place | London | SW1P 1WG